Zimelidine

Zimelidine is a drug that belongs to the class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). It was developed in the late 1970s by the Swedish pharmaceutical company Astra AB (now part of AstraZeneca). Zimelidine was the first SSRI to be marketed, but its use was discontinued in the early 1980s due to its association with a rare but serious condition called Guillain-Barré syndrome (GBS).

History

Zimelidine was discovered by a team led by Arvid Carlsson, who was awarded the Nobel Prize in Physiology or Medicine in 2000 for his work on neurotransmitters. The drug was introduced to the market in 1982 but was withdrawn in 1983 after reports of Guillain-Barré syndrome, a disorder in which the body's immune system mistakenly attacks part of its peripheral nervous system, in patients taking the drug.

Mechanism of Action

Zimelidine functions by inhibiting the reuptake of serotonin (5-HT), a neurotransmitter involved in the regulation of mood, appetite, and sleep, among other functions. By preventing the reuptake of serotonin, zimelidine increases the concentration of serotonin in the synaptic cleft, which is thought to contribute to its antidepressant effects.

Clinical Use

Before its withdrawal, zimelidine was used for the treatment of major depressive disorder (MDD) and other mood disorders. Its development and introduction marked a significant advancement in the treatment of depression, paving the way for the development of other SSRIs, which are now among the most commonly prescribed antidepressants.

Side Effects

The side effects of zimelidine were similar to those of other SSRIs and included nausea, dry mouth, dizziness, and insomnia. However, its association with Guillain-Barré syndrome, a potentially life-threatening condition, led to its withdrawal from the market.

Legacy

Despite its short-lived presence on the market, zimelidine had a lasting impact on the field of psychiatry and pharmacology. It demonstrated the potential of targeting the serotonin system to treat depression, leading to the development and widespread adoption of SSRIs, which have a more favorable side effect profile compared to earlier antidepressants.

See Also

• Antidepressant discontinuation syndrome
• History of depression
• List of withdrawn drugs

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian